Big Data and AI Can Guide Cannabis Medicine

大数据、AI可指导大麻医学

2021-08-30 23:00:12 CFN Media Group

本文共1487个字,阅读需4分钟

In order for cannabis medicine to make the big leap to mainstream acceptance, a few things likely have to take place. Doctors, not just cannabis providers, need to become more comfortable discussing and prescribing the plant. Regulations need to become more homogenous and universal, like the pharmaceutical industry. Pharma companies need to advance more cannabis-derived medicines for approval. In order for those things to happen, robust data around the efficacy of cannabis treatments needs to be gathered and widely understood. In the meantime, cannabis patients and providers are often stuck with a personal trial-and-error approach to finding the right treatment for their own needs. RYAH Group Inc. (CSE: RYAH) is one company that is pushing forward in all of these areas. The company’s smart delivery devices, database with over 200,000 users, and artificial intelligence-powered data engine combine to form a powerful Internet of Things solution with the potential to more fully legitimize cannabis medicine while making it more effective for current patients. Regulators like the United States Food and Drug Administration (FDA) need data to make informed decisions. Big pharma companies need data to even undertake research programs aimed at developing new potential drugs. Doctors need data to feel comfortable giving prescriptions or recommendations for treatment. Since the cannabis industry is so young, was prohibited for so long, and still faces a myriad of patchwork and inconsistent regulations, cannabis medicine is severely lacking the large datasets that are crucial for the industry’s development. In this regard, RYAH is well-positioned to provide all interested parties with the information necessary for growth and advancement. RYAH’s Data Sharing Benefits The company’s smart devices and data solutions are gaining traction with cannabis researchers across the globe. The controlled dosing, easily recorded personal feedback from patients, wealth of data stored in RYAH’s Cloud database, and AI-powered data interpretation and organization give researchers tools that make their studies more effective and efficient. RYAH is involved in trials and studies in Britain, Italy, Italy again, and the Channel Islands. The company also has deals in France and New Zealand for distribution and potential inclusion in clinical trials and major studies. RYAH’s goal is to provide regulators, researchers, and drug companies all the data they need to mainstream plant-based medicine, and it looks like the company is on its way. Click here to receive an investor presentation and corporate updates RYAH’s smart devices, connected apps, and AI data interpreter can help patients and doctors effectively hone a treatment regimen according to the patient’s own feedback combined with that of the other users in the system. Without the insights from a large patient pool and the ability to easily record, track, and interpret personal experiences and preferences, many cannabis patients can get a little lost. Which strain? What is the proper dose? Has this particular type of treatment worked for other people? Watch how Ryah technology Benefits to Patients and Doctors RYAH’s system offers control and assurance, not only to researchers and patients involved in clinical trial programs but also to normal, everyday medical cannabis users in search of a little guidance. To many, using cannabis presents a great unknown fraught with risks. RYAH helps to alleviate those concerns and bring the cannabis patient experience more in line with that of conventional patients. This type of system is right in line with the larger trend toward tele-health and the use of machine learning and artificial intelligence to improve patient outcomes. Overall, the market for remote treatment is growing at a 26.5% CAGR, expected to reach $475 billion in the next five years. It’s a huge trend in healthcare, and RYAH is at the forefront of the movement in the cannabis industry. The two aspects of RYAH’s business go hand in hand, improving treatments for cannabis patients while providing data and a platform that enables research and regulation that will further legitimize the industry as a whole. Keep an eye out for continued developments in the RYAH story. Click here to receive an investor presentation and corporate updates Disclaimer The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/ This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
为了让大麻药物获得主流认可,可能需要做一些事情。医生,不仅仅是大麻提供者,需要变得更舒服地讨论和开这种植物的处方。监管需要变得更加统一和普遍,就像制药行业一样。制药公司需要推进更多的大麻衍生药物获得批准。 为了使这些事情发生,需要收集和广泛理解关于大麻治疗功效的可靠数据。与此同时,大麻患者和提供者经常被困在个人试错方法中,以找到适合自己需求的正确治疗方法。RYAH集团公司(CSE:RYAH)是一家正在推进所有这些领域的公司。该公司的智能交付设备、拥有超过20万用户的数据库和人工智能驱动的数据引擎结合在一起,形成了一个强大的物联网解决方案,有可能更充分地使大麻药物合法化,同时使其对当前患者更有效。 像美国食品药品监督管理局(FDA)这样的监管机构需要数据来做出明智的决定。大型制药公司甚至需要数据来进行旨在开发新的潜在药物的研究项目。医生需要数据才能舒服地给出处方或治疗建议。 由于大麻行业如此年轻,被禁止了如此长的时间,仍然面临着无数拼凑和不一致的法规,大麻医学严重缺乏对该行业发展至关重要的大型数据集。在这方面,RYAH有能力为所有相关方提供发展和进步所需的信息。 RYAH的数据共享好处 该公司的智能设备和数据解决方案正在全球大麻研究人员中获得支持。受控的剂量、容易记录的患者个人反馈、存储在Ryah云数据库中的丰富数据,以及人工智能驱动的数据解释和组织,为研究人员提供了工具,使他们的研究更加有效和高效。RYAH参与了英国、意大利、意大利和海峡群岛的试验和研究。该公司在法国和新西兰也有分销交易,并有可能纳入临床试验和主要研究。 Ryah的目标是向监管者、研究人员和制药公司提供他们主流植物药物所需的所有数据,看起来该公司正在进行中。 单击此处接收投资者演示文稿和公司更新 Ryah的智能设备、连接的应用程序和AI数据解释器可以帮助患者和医生根据患者自己的反馈并结合系统中其他用户的反馈有效地磨练治疗方案。如果没有大量患者的洞察力和轻松记录、跟踪和解释个人经历和偏好的能力,许多大麻患者可能会迷失方向。哪一种?合适的剂量是多少?这种特殊类型的治疗对其他人有效吗? 观察Ryah技术如何造福于患者和医生 Ryah的系统不仅为参与临床试验项目的研究人员和患者提供控制和保证,也为寻找一点指导的正常、日常医用大麻使用者提供控制和保证。对许多人来说,使用大麻带来了巨大的未知风险。RYAH有助于减轻这些担忧,并使大麻患者的体验更符合传统患者的体验。 这种类型的系统符合远程医疗的大趋势,也符合使用机器学习和人工智能来改善患者结果的趋势。总体而言,远程治疗市场的复合增长率为26.5%,预计未来五年将达到4750亿美元。这是医疗保健领域的一个巨大趋势,RYAH站在大麻行业运动的最前沿。 Ryah业务的两个方面齐头并进,改善对大麻患者的治疗,同时提供数据和平台,使研究和监管能够进一步使整个行业合法化。密切关注RYAH故事的持续发展。 单击此处接收投资者演示文稿和公司更新 免责声明 以上文章为赞助内容。cannabisfn.com和CFN Media被雇来提高认识。请按以下链接查看我们概述赔偿的完整披露:http://www.cannabisfn.com/legal-disclaimer/ 本文由CFN Enterprises Inc.(OTCQB:CNFN)发表,该公司是CFN Media的所有者和运营商,CFN Media是行业领先的机构和数字金融媒体网络,致力于新兴的CBD和合法大麻行业。请致电+1(833)420-CNFN了解更多信息。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文